Upsurge in geriatric population that is highly susceptible to pain and chronic disorders has a positive impact on the market growth. In addition, rise in need for the development of advanced minimally invasive surgical techniques has propelled the demand for endoscopic RFA across healthcare settings, thus fueling the market growth.
However, dearth of skilled professionals that lack complete know-how of endoscopic RFA treatment impedes the market growth. Conversely, high untapped potential in the emerging economies is anticipated to offer significant profitable opportunities for the expansion of the market.
The endoscope + radiofrequency ablation (RFA) market is segmented based on application. On the basis of application, the market is categorized into cardiology applications, pain management, oncology applications, and others.
This report entails a detailed quantitative analysis of the current market trends from 2017 to 2025 to identify the prevailing opportunities along with strategic assessment of global endoscope + radiofrequency ablation (RFA) market.
Market size and estimations are based on comprehensive analysis of the applications and developments in the industry.
A qualitative analysis based on innovative products and devices facilitate the strategic business planning.
The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.
KEY MARKET SEGMENTS
KEY MARKET PLAYERS
Boston Scientific Corporation
Smith & Nephew Plc.
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.1.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Endoscope + radiofrequency ablation (RFA) market: Innovative products
3.2.1. Barex 360
3.2.2. Habib EUS RFA catheter
3.2.3. Temperature-resistant probes
3.3. Clinical trials: RFA and RFA + endoscope products in pipeline
3.4. Market dynamics
18.104.22.168. Increase in the prevalence of cancer and cardiac ailments across the globe
22.214.171.124. Large scale adoption of endoscopic RFA devices in pain management
126.96.36.199. High efficacy and short duration of the procedure
188.8.131.52. High costs associated with the RFA treatment
184.108.40.206. Limited awareness regarding available RFA + endoscope devices
220.127.116.11. Emerging indications for the endoscopic radiofrequency ablation
CHAPTER 4: ENDOSCOPE + RADIOFREQUENCY ABLATION (RFA) MARKET, BY APPLICATION
4.1.1. Market size and forecast
4.2. Oncology application
4.2.1. Market size and forecast
4.3. Pain management
4.3.1. Market size and forecast
4.4. Cardiology application
4.4.1. Market size and forecast
4.5. Other applications
4.5.1. Market size and forecast
CHAPTER 5: COMPANY PROFILES
5.1. Boston Scientific Corporation
5.1.1. Company overview
5.1.2. Company snapshot
5.1.3. Operating business segment
5.1.4. Business performance
5.1.5. Key strategic moves and developments
5.2. Conmed Corporation
5.2.1. Company overview
5.2.2. Company snapshot
5.2.3. Operating business segment
5.2.4. Business performance
5.2.5. Key strategic moves and developments
5.3. Medtronic Plc
5.3.1. Company overview
5.3.2. Company snapshot
5.3.3. Operating business segment
5.3.4. Business performance
5.3.5. Key strategic moves and developments
5.4. Smith & Nephew Plc
5.4.1. Company overview
5.4.2. Company snapshot
5.4.3. Operating business segment
5.4.4. Business performance
5.5. Stryker Corporation
5.5.1. Company overview
5.5.2. Company snapshot
5.5.3. Operating business segments
5.5.4. Business performance
5.5.5. Key strategic moves and developments
Radiofrequency ablation (RFA) utilizes thermal energy to accomplish targeted tissue destruction. RFA was initially studied for the treatment of dysplastic Barrettes esophagus (BE) within the gastrointestil (GI) tract, and this is still considered to be a common application of RFA. In addition, the indications for endoscopic RFA continue to evolve.
The global endoscope + RFA market is anticipated to grow at a significant rate during the forecast period, owing to factors, such as increase in the prevalence of cancer and cardiac ailments across the globe, surge in adoption of RFA devices in pain magement, and high efficacy and short duration of the procedure. However, high costs associated with the RFA treatment and limited awareness towards available endoscopic RFA devices are anticipated to hamper the market growth. On the contrary, the emerging indications for the endoscopic radiofrequency ablation are expected to offer lucrative growth opportunities for the market players.
On the basis of application, the market is classified into cardiology application, pain magement, oncology application, and other application. Among these, the cardiology application segment accounted for the largest share of the revenue generated in 2017 and is anticipated to maintain this trend throughout the forecast period. However, the oncology application segment is expected to grow at the fastest pace from 2018 to 2025.
Key Findings of the Endoscope + Radiofrequency Ablation (RFA) Market:
The pain magement segment accounted for approximately 29% of the global market share in 2017.
Europe accounted for more than 30.0% share of the global endoscope + RFA market in 2017 and is expected to maintain this trend throughout the forecast period.
India is anticipated to grow at the fastest pace in the Asia-Pacific market, registering a CAGR of 12.8% from 2018 to 2025.
U.S. has generated the highest revenue in 2017 in the North America market and is expected to maintain this domince throughout the forecast period.
North America was the leading revenue contributor to the global market in 2017 and is expected to maintain this domince throughout the forecast period. This is attributed to the fact that North America is an established market for radiofrequency device ablation technologies, wherein countries in this region adopt novel RFA devices including endoscope + RFA devices at the earliest. However, Asia-Pacific is expected to grow at the highest CAGR from 2018 to 2025, because this region is home to the worlds most diverse population groups and encompasses both developing and underdeveloped economies. With increase in burden of diseases across these countries, Asia-Pacific is anticipated to offer profitable opportunities for the market players focusing on expansion.
The major companies profiled in this report include Boston Scientific Corporation Conmed Corporation, Medtronic Plc (Covidien Plc), Smith & Nephew Plc, Stryker Corporation, Halyard Health, Inc., Abbott Laboratories (St. Jude Medical, Inc.), AngioDymics, Inc., Hologic, Inc., and AtriCure, Inc. Other prominent players in the value chain include Diros Technology, Inc., Arthrex, Inc., Biotronik, Cosman Medical, Inc., Fcare Systems, Johnson & Johnson (Biosense Webster & DePuy Mitek), Stockert GmbH, and ENDO-FLEX GmbH.
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.